Xeroderma Pigmentosum Type C Primary Skin Fibroblasts Overexpress HGF and Promote Squamous Cell Carcinoma Invasion in the Absence of Genotoxic Stress.

HGF/SF fibroblasts squamous cell carcinoma xeroderma pigmentosum

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 14 04 2024
revised: 15 05 2024
accepted: 24 05 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Xeroderma pigmentosum (XP) is a very rare recessive disease caused by the incapacity to resolve ultraviolet-induced DNA lesions through Nucleotide Excision Repair (NER). Most XP patients suffer from aggressive skin carcinoma and melanoma at a very early age (<8). Our previous results showed that primary XP fibroblasts isolated from healthy (non-photo-exposed) skin negatively impact the extracellular matrix and fail to activate the innate immune system. Here, we show for the first time that XP-C fibroblasts also play a major role in cancer cell invasion ex vivo and in vivo through the overexpression of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) in the absence of genotoxic attacks. The use of inhibitors of the activation of the HGF/SF pathway counteracted the effects of XP fibroblasts on the growth of cancer cells, suggesting new perspectives in the care of XP patients.

Identifiants

pubmed: 39409898
pii: cancers16193277
doi: 10.3390/cancers16193277
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : French Government (National Research Agency, ANR; CNRS; INSERM) through the 'Invest-ments for the Future' LABEX SIGNALIFE
ID : ANR-11-LABX-0028-01
Organisme : Association pour la Recherche contre le Cancer
ID : ARC, SFI201212055859
Organisme : Société Française de Dermatologie
ID : n°174761, UMR7284

Auteurs

Sahar Al-Qaraghuli (S)

INSERM U1081-CNRS UMR7284-UNS, CEDEX 02, F-06107 Nice, France.
Faculté de Médicine, 2ème étage, CNRS UMR 6267-INSERM U998-UNSA, F-06107 Nice Cedex 2, France.

Yannick Gache (Y)

INSERM U1081-CNRS UMR7284-UNS, CEDEX 02, F-06107 Nice, France.
Faculté de Médicine, 2ème étage, CNRS UMR 6267-INSERM U998-UNSA, F-06107 Nice Cedex 2, France.

Maria Goncalves-Maia (M)

INSERM U1081-CNRS UMR7284-UNS, CEDEX 02, F-06107 Nice, France.
Faculté de Médicine, 2ème étage, CNRS UMR 6267-INSERM U998-UNSA, F-06107 Nice Cedex 2, France.

Damien Alcor (D)

Faculté de Médicine, 2ème étage, CNRS UMR 6267-INSERM U998-UNSA, F-06107 Nice Cedex 2, France.
INSERM U1065, C3M, Microscopy Facility, F-06200 Nice, France.

Elodie Muzotte (E)

BRIC, UMR 1312, Inserm, Université de Bordeaux, F-33076 Bordeaux, France.

Walid Mahfouf (W)

BRIC, UMR 1312, Inserm, Université de Bordeaux, F-33076 Bordeaux, France.

Hamid-Reza Rezvani (HR)

BRIC, UMR 1312, Inserm, Université de Bordeaux, F-33076 Bordeaux, France.
Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, F-33000 Bordeaux, France.

Thierry Magnaldo (T)

INSERM U1081-CNRS UMR7284-UNS, CEDEX 02, F-06107 Nice, France.
Faculté de Médicine, 2ème étage, CNRS UMR 6267-INSERM U998-UNSA, F-06107 Nice Cedex 2, France.

Classifications MeSH